Intrathecal Morphine Compared to Conventional Medical Management for Pain Control and Opioid-related Side Effects

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

7 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-10-31

Study Completion Date

2015-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study compares two different ways to treat pain. The two ways are:

1. continuing to take current pain medication(s) or
2. receiving morphine, a pain medication from a drug pump (a system to deliver drug to your body) that is implanted.

None of the procedures or products used in this study are experimental. The length the study will be about 25 weeks (between 5½ to 6½ months). The purpose of this study is to compare pain and opioid side effects between people who get a drug pump and people who do not get a drug pump that will stay on their current pain medication treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Clinical Evaluation of Implantable Pump System For Safety And Delivery Accuracy In Patients Requiring Intrathecal Administration Of Morphine Sulfate For Chronic Pain

NCT01185470

Cancers Chronic Pain

COMPLETED PHASE2/PHASE3

Post-market, Randomized, Controlled, Prospective Study Evaluating Intrathecal Pain Medication (IT) Versus Conventional Medical Management (CMM) in the Non-cancer, Refractory, Chronic Pain Population

NCT04096391

Chronic Nonmalignant Pain Pain, Intractable Pain, Chronic

COMPLETED NA

Embrace TDD: Post-Market Study to Evaluate Intrathecal Morphine as an Alternative to Systemic Opioids for Chronic Pain

NCT03761277

Chronic Non-malignant Pain Chronic Pain Pain, Back +1 more

COMPLETED PHASE4

Safety and Efficacy Study of Hydromorphone Hydrochloride by Intrathecal Administration

NCT01709721

Management of Chronic Pain

COMPLETED PHASE3

Prospective Evaluation of Intrathecal Targeted Drug Delivery for Cancer Associated Pain

NCT05674240

Cancer Pain Chronic Pain Cancer Associated Pain +1 more

ACTIVE_NOT_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This was a randomized, controlled, open-label, multi-center, prospective post-market study to assess pain control and opioid-related side effects following a route of delivery change to low dose IT morphine therapy from systemic opioid therapy. Subjects with nonmalignant, chronic, intractable pain who were experiencing inadequate pain relief and/or intolerable side effects from systemic opioid therapy receiving ≤300 mg/day morphine equivalent dose were eligible for screening. Additionally, the subjects had no known history of sleep apnea and were candidates for IT morphine administration via the SynchroMed Infusion System. Subjects must not have previously undergone an intrathecal/epidural trial for pump infusion therapy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

IT group (Intrathecal Morphine Sulfate)

SynchroMed Infusion System and Intrathecal Morphine Sulfate

Group Type OTHER

SynchroMed Infusion System and Intrathecal Morphine Sulfate

Intervention Type DEVICE

Following a successful test of Intrathecal Morphine Sulfate, subjects will undergo surgery to implant the drug pump (SynchroMed Infusion System) and spinal catheter. The pump will deliver morphine directly to the spinal cord for pain control.

Conventional Medical Management

Conventional Medicine, and then SynchroMed Infusion System and Intrathecal Morphine Sulfate

Group Type OTHER

SynchroMed Infusion System and Intrathecal Morphine Sulfate

Intervention Type DEVICE

Following a successful test of Intrathecal Morphine Sulfate, subjects will undergo surgery to implant the drug pump (SynchroMed Infusion System) and spinal catheter. The pump will deliver morphine directly to the spinal cord for pain control.

Conventional Medicine

Intervention Type OTHER

Subjects will continue to use pain medications as prescribed by their doctor.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SynchroMed Infusion System and Intrathecal Morphine Sulfate

Following a successful test of Intrathecal Morphine Sulfate, subjects will undergo surgery to implant the drug pump (SynchroMed Infusion System) and spinal catheter. The pump will deliver morphine directly to the spinal cord for pain control.

Intervention Type DEVICE

Conventional Medicine

Subjects will continue to use pain medications as prescribed by their doctor.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

SynchroMed infusion system Intrathecal morphine sulfate Infumorph Targeted drug delivery Spinal morphine Intrathecal morphine Standard of Care

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Signed and dated Medtronic/IRB approved Informed Consent Form and HIPAA Authorization prior to any study procedures being performed
* Willing and able to attend visits and comply with the study protocol
* Willing and able to abstain from alcohol consumption for the study duration
* At least 18 years of age
* Male or non-pregnant, non-lactating female
* Currently receiving \</= 300 mg/day morphine equivalent of systemic opioids at screening
* Used a stable dose of opioids (no change in type or prescribed frequency or dose) for 30 days prior to the Screening as documented in the medical history
* Used chronic systemic opioids for at least 6 months prior to Screening as documented in medical history

Per investigator's medical assessment and the subject's medical history, the subject is/has:

* A new candidate for chronic intrathecal drug therapy (including no prior intrathecal/epidural trial for pump infusion therapy)
* A diagnosis of nonmalignant, chronic intractable pain as documented in the medical history
* Medically stable and able to undergo surgery for implantation of the SynchroMed Infusion System
* Completed a psychological evaluation within 6 months prior to Screening

Exclusion Criteria

* Psychological or other health conditions, financial, and/or legal concerns (within 3 months prior to Screening) that would interfere with the subject's ability to fulfill the requirements of the protocol as per the investigator's opinion
* A history of alcohol abuse or any illicit drug use within 2 years prior to Screening
* A positive urine test for illicit drugs at Screening (Exception: If subject has a physician's prescription for an illicit drug; for example, medical marijuana)
* Known diagnosis of moderate to severe sleep apnea.
* Prescribed Continuous Positive Airway Pressure (CPAP), Adaptive Servo-Ventilation (ASV) therapy or an oral appliance prescribed for the treatment of moderate to severe sleep apnea (current or previous history)
* An active malignancy or has been diagnosed with cancer and has not been in remission for at least 1 year prior to screening
* An implanted electrical stimulation device(s) or if the subject is expected to require one of these during the course of the study
* Planned to enroll or is currently enrolled in another investigational drug or investigational medical device study or has participated in an investigational drug or medical device study within 30 days prior to Screening

Prior to Randomization, a subject will be excluded if:

* Diary does not meet compliance
* Mean diary-reported 12-hour NPRS \< 6 (on 0 to 10 scale, as reported over 5 days)
* Positive urine test for alcohol at Baseline
* Negative urine test for opioids at Baseline
* Baseline sleep study (PSG) with SaO2 \<=80% for \>= 5 consecutive minutes, and/or an Apnea-Hypopnea Index (AHI) \>=15.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No